UA122237C2 - Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування - Google Patents
Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування Download PDFInfo
- Publication number
- UA122237C2 UA122237C2 UAA201802841A UAA201802841A UA122237C2 UA 122237 C2 UA122237 C2 UA 122237C2 UA A201802841 A UAA201802841 A UA A201802841A UA A201802841 A UAA201802841 A UA A201802841A UA 122237 C2 UA122237 C2 UA 122237C2
- Authority
- UA
- Ukraine
- Prior art keywords
- disease
- methyl
- compound
- mmol
- stage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA122237C2 true UA122237C2 (uk) | 2020-10-12 |
Family
ID=57200096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201802841A UA122237C2 (uk) | 2015-10-07 | 2016-10-05 | Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (enExample) |
| EP (3) | EP3770146B1 (enExample) |
| JP (2) | JP6657413B2 (enExample) |
| KR (2) | KR102667386B1 (enExample) |
| CN (3) | CN113024467B (enExample) |
| AU (3) | AU2016333963C1 (enExample) |
| BR (1) | BR112018006866B1 (enExample) |
| CA (1) | CA3000431A1 (enExample) |
| CO (1) | CO2018004473A2 (enExample) |
| DK (1) | DK3359528T3 (enExample) |
| EA (1) | EA037371B1 (enExample) |
| ES (3) | ES2949852T3 (enExample) |
| HU (1) | HUE058154T2 (enExample) |
| IL (3) | IL258225B (enExample) |
| JO (3) | JO3738B1 (enExample) |
| MA (2) | MA52098A (enExample) |
| MX (3) | MX380281B (enExample) |
| MY (1) | MY203081A (enExample) |
| PH (1) | PH12018500762A1 (enExample) |
| PL (1) | PL3359528T3 (enExample) |
| PT (1) | PT3359528T (enExample) |
| SG (1) | SG10201906400SA (enExample) |
| TW (3) | TWI730006B (enExample) |
| UA (1) | UA122237C2 (enExample) |
| WO (1) | WO2017062468A1 (enExample) |
| ZA (4) | ZA201802029B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037371B1 (ru) * | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| WO2017180818A1 (en) | 2016-04-13 | 2017-10-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CA3036587A1 (en) * | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| JP7065839B2 (ja) * | 2016-10-05 | 2022-05-12 | ミトブリッジ，インコーポレーテッド | 急性腎障害を処置する方法 |
| US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CA3212825A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| US20240358681A1 (en) | 2021-06-02 | 2024-10-31 | Mitobridge, Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| CZ20013000A3 (cs) | 1999-02-26 | 2002-02-13 | Merck & Co., Inc. | Nové sulfonamidové sloučeniny a jejich pouľití |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| HUP0303763A3 (en) | 2000-08-17 | 2004-06-28 | Pfizer | Substituted imidazoles as tafia inhibitors, process for their preparation and pharmaceutical compositions containing them |
| RU2328483C2 (ru) * | 2002-08-29 | 2008-07-10 | Мерк Энд Ко., Инк. | Индолы, обладающие противодиабетической активностью |
| AU2003241836A1 (en) | 2002-10-03 | 2004-04-23 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| CN1886124A (zh) | 2003-09-26 | 2006-12-27 | 日本烟草产业株式会社 | 抑制残余脂蛋白产生的方法 |
| WO2006027135A1 (en) | 2004-09-06 | 2006-03-16 | F. Hoffmann-La Roche Ag | 4-aminomethyl benzamidine derivatives and their use as factor viiia inhibitors |
| KR20070097574A (ko) | 2005-02-15 | 2007-10-04 | 에프. 호프만-라 로슈 아게 | Ｐｐａｒ 활성화제로서의 아미드 유도체 |
| TW200800872A (en) | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
| KR20080094806A (ko) | 2006-01-30 | 2008-10-24 | 트랜스테크 파르마, 인크. | 치환된 이미다졸 유도체 및 이의 ＰＴＰａｓｅ 억제제로서의 용도 |
| KR20080098548A (ko) | 2006-03-28 | 2008-11-10 | 노파르티스 아게 | Ｇ 단백질 관련 질환의 치료를 위한 아미드 유도체 및 그의투여 |
| JP5290749B2 (ja) | 2006-04-18 | 2013-09-18 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) * | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008221718A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| JP2011507970A (ja) | 2007-12-28 | 2011-03-10 | ザ ソーク インスティテュート フォー バイオロジカル スタディーズ | 筋肉の能力および緊張を向上させるための方法 |
| WO2014033088A1 (en) | 2012-08-28 | 2014-03-06 | Koc Universitesi | Bone plate |
| CA2908695A1 (en) | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EA037371B1 (ru) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| WO2017180818A1 (en) | 2016-04-13 | 2017-10-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| JP7065839B2 (ja) | 2016-10-05 | 2022-05-12 | ミトブリッジ，インコーポレーテッド | 急性腎障害を処置する方法 |
| CA3036587A1 (en) * | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| EP3562822B1 (en) * | 2016-12-30 | 2021-03-10 | Mitobridge, Inc. | Poly-adp ribose polymerase (parp) inhibitors |
-
2016
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA122237C2 (uk) | Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування | |
| EA018901B1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
| EP2330098A1 (en) | Compound with agitation effect on peroxisome proliferator-activated receptor , and preparation method and use thereof | |
| TW200406371A (en) | Amide linker peroxisome proliferator activated receptor modulators | |
| CN111393421B (zh) | 丁烯酸内酯类衍生物及其制备方法与应用 | |
| EA039833B1 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| WO2024192252A2 (en) | Use of small molecules to increase hypoxia inducible factor (hif) activity | |
| CN103755562B (zh) | 一种洛伐他汀羟基酸化物的制备方法、组合物、组合物的制备方法及其应用 | |
| TW202045491A (zh) | 唑衍生物 | |
| WO2011103127A1 (en) | Treatment of metabolic syndrome with piperidine amides |